novo nordisk glp 1 drugs Novo, Lilly weight-loss should be first option obesity treatments, European doctors say Weight-loss drugs becoming better value
Description
A 2024 safety review in ScienceDirect noted that tirzepatide may have slightly better GI tolerability than semaglutide, likely because of its dual mechanism ( ScienceDirect , 2024)

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

8 Saxenda [prescribing information]
We are conveniently located at 2504 Raeford Road #101 Fayetteville NC

In its Acceleration Plan to Stop Obesity, adopted in 2022, WHO highlights many different factors contribute to obesity and that the matter is not just a matter of individual responsibility

Of the 1822 participants on a GLP-1 RA, 72% (1309 individuals) were still on therapy for at least 3 years
